Project description:AZIN2 regulates adipogenesis and acetyl-coA levels in adipocyte progenitors. We investigated here how AZIN2 deficiency affects histone acetylation in adipocyte progenitors.
Project description:FACS-purified adipocyte progenitors from murine subcutaneous adipose tissue were cultured under conditions promoting general adipogenic differentiation or beige/brite adipocyte differentiation (treatment with cPGI2). Time course expression profiling was performed during differentiation. In addition, some cultures of differentiated adipocytes were stimulated with norepinephrine for 3 hours. In parallel, differentiation and norepinephrine stimulation of progenitors from interscapular brown fat was performed and profiled.
Project description:Lin-Sca-1+ adipocyte progenitors from subcutaneous adipose tissue of wild-type and Cited4-/- female mice were cultured under conditions promoting general adipogenic differentiation or beige/brite adipocyte differentiation (treatment with Rosi). Cells were harvested 48 post-induction of differentiation.
Project description:FACS-purified adipocyte progenitors from murine subcutaneous adipose tissue were cultured under conditions promoting general adipogenic differentiation or beige/brite adipocyte differentiation (treatment with cPGI2) in the presence of absence of Jak inhibitor I (JakiI), which targets all Jak family members. The cells were harvested 24 hours after induction of differentiation.
Project description:AZIN2 regulates adipocyte progenitor differentiation. Here we investigated how AZIN2 deficiency affects the profile of adipocyte progenitors. To this end, Azin2-/- and wild-type male mice were fed for 8 weeks a high-fat diet, subcutaneous adipose tissue was isolated and single-cell RNA-seq was performed in CD45-CD31- cells of the stromal vascular fraction.
Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.